EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapies
Retrieved on:
Tuesday, November 9, 2021
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, Stem cell, University, RNA editing, Cancer, Inosine, Lists of diseases, MD, B cell, CEO, RNA, Potency (pharmacology), Technology, Research, Gamm, RPE, Partnership, Peking University, Doctor of Philosophy, University of Wisconsin–Madison, Adenosine, Translation, ADAR, Enzyme, Gene editing, Patient, Visual Science, Pharmaceutical industry, Vaccine, the David Gamm Laboratory, EdiGene, Inc, THE DAVID GAMM LABORATORY, EDIGENE, INC
LEAPER (Leveraging endogenous ADAR for programmable editing of RNA) employs short engineered ADAR-recruiting RNAs (arRNAs) to recruit native ADAR enzymes to change specific adenosine to inosine.
Key Points:
- LEAPER (Leveraging endogenous ADAR for programmable editing of RNA) employs short engineered ADAR-recruiting RNAs (arRNAs) to recruit native ADAR enzymes to change specific adenosine to inosine.
- LEAPER is a robust, precise, and efficient RNA editing technology uniquely suited for in vivo therapies with broad therapeutic applicability.
- This collaboration furthers our efforts in RNA editing and in vivo gene-editing therapies, said Dong Wei, Ph.D., CEO of EdiGene.
- EdiGene is a global, clinical-stage biotechnology company focused on translating gene editing technologies into transformative therapies for patients with serious genetic diseases and cancer.